December 13, 2008 -- According to Thomson Reuters, China will be the world's leading technology innovator by 2012; the ChinaBio® Investor Forum awarded prestigious "Most Promising Company" awards to Fountain Medical and ProteLight Pharmaceutical & Biotechnology; China Aoxing Pharma received an SFDA production license for an OTC pain drug; Crucell said the SFDA released its hepatitis B vaccine for registration and quality control; China Sky One Medica received approval from the SFDA for two new drugs; we took a deep look at China Sky One's growing product portfolio and very deep pipeline; RHEI Pharma has begun the final China clinical trial for a locally active antifungal; BioDuro announced it has been awarded full accreditation from the AAALAC; Cook Medical will open a combined distribution and customer service center in Shanghai; and China Shenghuo Pharma resumed trading after bringing its financial reports up to date. More details... Stock Symbols: (OTCBB: CAXG) (NSDQ: CRXL) (NSDQ: CSKI) (NYSE Alternext US: KUN)
